Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
IPO Year: 2021
Exchange: NASDAQ
Website: boltbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2022 | $45.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/6/2022 | Overweight → Equal-Weight | Morgan Stanley | |
| 11/10/2021 | $35.00 → $33.00 | Outperform | SVB Leerink |
| 8/16/2021 | $34.00 → $35.00 | Outperform | SVB Leerink |
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results. Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from Benzinga Pro. Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers AERWINS Technologies Inc. (NASDAQ:AWIN) shares surged
Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Outperform to Market Perform and lowers the price target from $3 to $1.
Gainers SINTX Techs (NASDAQ:SINT) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. Nutriband (NASDAQ:NTRB) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. Bone Biologics (NASDAQ:BBLG) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. OptimizeRx (NASDAQ:OPRX) shares moved upwards by 22.8% to $12.87. The market value of their
Jones Trading analyst Soumit Roy downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold.
HC Wainwright & Co. analyst Edward White downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank analyst Bryan Keane downgraded the rating on Accenture plc (NYSE:ACN) from Buy to Hold, while slashing the price target from $409 to $295. Accenture shares declined 0.2% to close at $306.95 on Tuesday. See how other analysts view this stock. Stifel analyst Stephen Willey downgraded Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares slipped 0.8% to settle at $1.32 on Tuesday. See how other analysts view th
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. Arcutis Biotherapeutics reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents. Quarterly sales clocked in at $49.57 million, beating the analyst consensus estimate of $14.68 million, according to data from Benzinga Pro. Arcutis Biotherapeutics shares jumped 29% to $10.49 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) gained 113.8% to $0
Gainers SINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 days ago. Arcutis Biotherapeutics (NASDAQ:ARQT) stock increased by 18.92% to $9.67. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. MultiPlan (NYSE:MPLN) stock increased by 17.24% to $0.66. The market value of their outstanding shares is at $426.5 million. CASI Pharmaceuticals (NASDAQ:CASI) shares moved upwards by 15.45% to $3.66. The company's market cap stands at $49.0 million. As per the press release, Q1 earnings
Guggenheim analyst Michael Schmidt downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Neutral.
Stifel analyst Stephen Willey downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold and lowers the price target from $6 to $1.5.
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
3 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Development to oversee all clinical activities; Edith Perez moving to an advisory roleCash balance of $112.8 million now expected to fund the Company into second half 2026, including generation of clinic
Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference call and webcast today at 8:00 a.m. ET/5:00 a.m. PT REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the presentation of interim clinical data from the company's ongoing Phase 1/2 study of BDC-1001, the company's lead immune-stimulat
REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the company will be presenting interim clinical data in a virtual poster on BDC-1001, starting on December 6, 2021 in conjunction with the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2021 taking place on December 8 - 11, 2021. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjug
10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
DEFA14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13D/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13D/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
SC 13D/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose-escalation trial of BDC-1001 at the SITC 39th Annual MeetingBDC-4182 on track to start clinical trial in second quarter 2025Cash balance of $84.4 million as of September 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter e
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 do
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside chat on Friday, Sept. 6, at 7:00 a.m. EDT (4:00 a.m. PDT)H.C. Wainwright 26th Annual Global Investment ConferenceCompany presentation available on Monday, Sept. 9, at 7:00am EDT (4:00 a.m. PDT) A webcast of the presentations will be available on the Events and Presentations page of Bolt's website at www.boltbio.com. Archived replays will be a
Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingCash balance of $97.5 million as of June 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. "During the second quarter, we con
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Development to oversee all clinical activities; Edith Perez moving to an advisory roleCash balance of $112.8 million now expected to fund the Company into second half 2026, including generation of clinic
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025 REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. "We made substantial progress a
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts. A live webcast of the presentation will be available on the Events and Presentations page of Bolt's website at www.boltbio.com. Archived replays will be available for 30 days following the event. About Bolt Biotherapeutics, Inc.Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersPoster detailing trial design and rationale to be presented at the 2023 San Antonio Breast Cancer Symposium on Wednesday, December 6 REDWOOD CITY, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), as a sing
Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $45.00 previously
Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight
SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $33.00 from $35.00 previously
SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $35.00 from $34.00 previously
SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $33.00 from $37.00 previously
SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $37.00 from $36.00 previously
SVB Leerink initiated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $36.00
Morgan Stanley initiated coverage of Bolt Biotherapeutics with a rating of Overweight and set a new price target of $45.00
Guggenheim initiated coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $42.00
Stifel Nicolaus initiated coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $40.00
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. "Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "As we continue to advance our immuno-oncology pipeline programs in the clinic, Laura brings important strategic perspective from leading and executing more than 50 transact
REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointment of Nicole Onetto, M.D., to its Board of Directors effective Dec. 14, 2021. "Nicole's extensive experience in clinical development and translational research makes her an excellent addition to the Bolt Biotherapeutics Board of Directors. Nicole's work overseeing oncology drug development programs at cancer research institutions, biotechnology and pharmaceutical compan
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien